FDC Ltd Q4 FY26: Profit Soars 167%, Revenue Up 19%, US Business Recovers

Net Profit: ₹103 crore (up 167.4% YoY)
Revenue: ₹585 crore (up 18.9% YoY)

Reader Takeaway: Q4 recovery driven by US business and margin gains, but domestic full-year growth subdued.

What just happened

FDC Limited announced its financial results for the fourth quarter and full year of FY26. The company reported a significant 167.4% year-on-year jump in net profit to ₹103 crore for Q4 FY26. This was driven by a robust 18.9% increase in revenue from operations, reaching ₹585 crore. EBITDA also saw a substantial rise of 97.0% to ₹106 crore, with EBITDA margins expanding to 18.2% from 11.0% in the same quarter last year.

Why this matters

The strong Q4 performance indicates a potential turnaround for FDC, especially with the recovery in its US business and improved operational efficiencies leading to better margins. The US FDA approval for Fluconazole Tablets is a positive development for future export potential.

The backstory

While Q4 FY26 showed strong recovery, the full-year FY26 revenue grew by a more modest 3.0% to ₹2,171 crore. The domestic formulations segment, which is the largest revenue contributor, saw only 0.1% growth for the full year, facing pressure from key brands like Zifi, Electral, and Enerzal. However, Q4 saw an 8.5% growth in this segment.

The US business, previously facing challenges, showed a significant recovery in Q4 FY26, with overall US business revenue growing by 46.9% and supplies revenue up by 165.1%.

What changes now

The company's focus will likely be on sustaining the Q4 momentum, capitalizing on the US FDA approval for Fluconazole Tablets, and reviving growth in key domestic brands. The improved EBITDA margins suggest better cost management and operational leverage.

Risks to watch

Potential risks include the sustainability of improved margins, competitive pressures on key domestic brands, and any unforeseen regulatory challenges in international markets.

Peer comparison

FDC operates in the pharmaceutical sector, which is competitive. Companies like Ajanta Pharma, Alkem Laboratories, and Cipla also focus on formulations and API businesses. FDC's Q4 performance highlights its ability to navigate challenges and achieve significant profit growth, but its full-year domestic growth lags some peers.

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹585 crore (+18.9% YoY)
• Q4 FY26 EBITDA Margin: 18.2% (vs 11.0% in Q4 FY25)
• Q4 FY26 PAT: ₹103 crore (+167.4% YoY)
• FY26 Revenue: ₹2,171 crore (+3.0% YoY)
• US Business Revenue Growth (Q4 FY26): +46.9%
• Fluconazole Tablets received US FDA approval.

What to track next

Investors will be keen to watch the performance of the domestic formulations segment in the upcoming quarters, the impact of the new US FDA-approved product, and the continued trend in EBITDA margins.